Acceleration Biopharmaceuticals

Acceleration Biopharmaceuticals is a biotechnology company focused on developing next-generation glucocorticoid therapies for patients with rare and inflammatory diseases. The company's lead program is centered on a novel dissociative glucocorticoid receptor ligand designed to maintain the potent anti-inflammatory benefits of traditional steroids while significantly reducing the systemic side effects that typically limit their long-term use. By optimizing the therapeutic index of these compounds, Acceleration Biopharmaceuticals aims to provide safer, more effective treatment options for conditions such as Duchenne muscular dystrophy. The company leverages deep expertise in steroid chemistry and muscle biology to advance its pipeline toward clinical development.